JP4558948B2 - 卵巣癌において過剰発現される膜貫通型セリンプロテアーゼおよびその使用 - Google Patents

卵巣癌において過剰発現される膜貫通型セリンプロテアーゼおよびその使用 Download PDF

Info

Publication number
JP4558948B2
JP4558948B2 JP2000602268A JP2000602268A JP4558948B2 JP 4558948 B2 JP4558948 B2 JP 4558948B2 JP 2000602268 A JP2000602268 A JP 2000602268A JP 2000602268 A JP2000602268 A JP 2000602268A JP 4558948 B2 JP4558948 B2 JP 4558948B2
Authority
JP
Japan
Prior art keywords
tadg
seq
protein
dna fragment
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2000602268A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002537791A5 (https=
JP2002537791A (ja
Inventor
ジェイ オブライアン，ティモシー
ジェイ アンダーウッド，ローウェル
Original Assignee
ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティー オブ アーカンソー システム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティー オブ アーカンソー システム filed Critical ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティー オブ アーカンソー システム
Publication of JP2002537791A publication Critical patent/JP2002537791A/ja
Publication of JP2002537791A5 publication Critical patent/JP2002537791A5/ja
Application granted granted Critical
Publication of JP4558948B2 publication Critical patent/JP4558948B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6472—Cysteine endopeptidases (3.4.22)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2000602268A 1999-03-03 2000-03-02 卵巣癌において過剰発現される膜貫通型セリンプロテアーゼおよびその使用 Expired - Fee Related JP4558948B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/261,416 US6291663B1 (en) 1999-03-03 1999-03-03 TADG-12: a novel transmembrane serine protease overexpressed in a ovarian carcinoma
US09/261,416 1999-03-03
PCT/US2000/005612 WO2000052044A1 (en) 1999-03-03 2000-03-02 Transmembrane serine protease overexpressed in ovarian carcinoma and uses thereof

Publications (3)

Publication Number Publication Date
JP2002537791A JP2002537791A (ja) 2002-11-12
JP2002537791A5 JP2002537791A5 (https=) 2007-04-19
JP4558948B2 true JP4558948B2 (ja) 2010-10-06

Family

ID=22993212

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000602268A Expired - Fee Related JP4558948B2 (ja) 1999-03-03 2000-03-02 卵巣癌において過剰発現される膜貫通型セリンプロテアーゼおよびその使用

Country Status (6)

Country Link
US (2) US6291663B1 (https=)
EP (1) EP1157035A4 (https=)
JP (1) JP4558948B2 (https=)
AU (1) AU765471B2 (https=)
CA (1) CA2362830C (https=)
WO (1) WO2000052044A1 (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030022293A1 (en) * 1997-09-18 2003-01-30 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030039648A1 (en) * 1998-09-16 2003-02-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US20030113842A1 (en) * 1998-03-11 2003-06-19 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
IL139988A0 (en) * 1998-06-01 2002-02-10 Urogenesys Inc Tumor antigen useful in diagnosis and therapy of prostate and colon cancer
US7037667B1 (en) 1998-06-01 2006-05-02 Agensys, Inc. Tumor antigen useful in diagnosis and therapy of prostate and colon cancer
US6902892B1 (en) * 1998-10-19 2005-06-07 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
US6942978B1 (en) * 1999-03-03 2005-09-13 The Board Of Trustees Of The University Of Arkansas Transmembrane serine protease overexpressed in ovarian carcinoma and uses thereof
US6720146B2 (en) * 1999-09-10 2004-04-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US20030232056A1 (en) 1999-09-10 2003-12-18 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
IL149340A0 (en) 1999-11-18 2002-11-10 Corvas Int Inc Nucleic acids encoding endotheliases, endotheliases and uses thereof
CA2399058A1 (en) * 2000-02-02 2001-08-09 Transgene S.A. Targeting peptides
US6797504B1 (en) * 2000-09-08 2004-09-28 Dendreon San Diego Llc Inhibitors of serine protease activity of matriptase or MTSP1
EP1252300B1 (en) * 2000-02-03 2011-01-19 Dendreon Corporation Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
US7700341B2 (en) 2000-02-03 2010-04-20 Dendreon Corporation Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
US7265216B2 (en) * 2000-03-02 2007-09-04 The Board Of Trustees Of The University Of Arkansas System Transmembrane serine protease overexpressed in ovarian carcinoma and uses thereof
EP1280923A2 (en) 2000-04-28 2003-02-05 Millennium Pharmaceuticals, Inc. 14094, a human trypsin family member and uses thereof
JP2008289482A (ja) * 2000-11-14 2008-12-04 Corixa Corp 卵巣癌の治療および診断のための組成物および方法
US20060063152A1 (en) * 2000-12-22 2006-03-23 Osamu Ohara Novel gene and protein encoded by the gene
US20040086875A1 (en) * 2001-11-05 2004-05-06 Agee Michele L. Novel proteins and nucleic acids encoding same
US7601825B2 (en) 2001-03-05 2009-10-13 Agensys, Inc. Nucleic acid and corresponding protein entitled 121P1F1 useful in treatment and detection of cancer
US6924358B2 (en) * 2001-03-05 2005-08-02 Agensys, Inc. 121P1F1: a tissue specific protein highly expressed in various cancers
WO2002072786A2 (en) 2001-03-13 2002-09-19 Corvas International, Inc. Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon
AU2002254357A1 (en) 2001-03-22 2002-10-08 Dendreon Corporation Nucleic acid molecules encoding serine protease cvsp14, the encoded polypeptides and methods based thereon
CA2442089A1 (en) 2001-03-27 2002-10-03 Dendreon San Diego Llc Nucleic acid molecules encoding a transmembran serine protease 9, the encoded polypeptides and methods based thereon
US7112430B2 (en) 2001-05-14 2006-09-26 Dendreon Corporation Nucleic acid molecules encoding a transmembrane serine protease 10, the encoded polypeptides and methods based thereon
WO2003088898A2 (en) * 2002-04-17 2003-10-30 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
AU2002357004A1 (en) * 2001-11-20 2003-06-10 Dendreon San Diego Llc Nucleic acid molecules encoding serine protease 17, the encoded polypeptides and methods based thereon
US20040001801A1 (en) * 2002-05-23 2004-01-01 Corvas International, Inc. Conjugates activated by cell surface proteases and therapeutic uses thereof
US20090163386A1 (en) * 2002-11-27 2009-06-25 Elementis Specialties, Inc. Compositions for drilling fluids useful to produce flat temperature rheology to such fluids over a wide temperature range and drilling fluids containing such compositions
US7799742B2 (en) * 2008-03-07 2010-09-21 Elementis Specialties Inc. Equivalent circulating density control in deep water drilling
US7345010B2 (en) 2002-11-27 2008-03-18 Elementis Specialties, Inc. Compositions for drilling fluids useful to provide flat temperature rheology to such fluids over a wide temperature range and drilling fluids containing such compositions
WO2004099779A1 (en) * 2003-05-05 2004-11-18 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human transmembrane serine protease 3 (tmprss3)
JP4880484B2 (ja) * 2004-02-20 2012-02-22 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 唾液ｍＲＮＡプロファイリング、バイオマーカーならびに関連した方法およびキット
KR101543622B1 (ko) 2006-10-17 2015-08-11 온코세라피 사이언스 가부시키가이샤 Ｍｐｈｏｓｐｈ1 또는 ｄｅｐｄｃ1 폴리펩티드를 발현하는 암에 대한 펩티드 백신
JP5564730B2 (ja) 2011-08-12 2014-08-06 オンコセラピー・サイエンス株式会社 Ｍｐｈｏｓｐｈ１ペプチドおよびそれを含むワクチン
SG11201802286PA (en) 2015-10-08 2018-04-27 Oncotherapy Science Inc Mphosph1-derived peptide, and vaccine including same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998041656A1 (en) * 1997-03-19 1998-09-24 The Board Of Trustees Of The University Of Arkansas Compositions and method for the early diagnosis of ovarian cancer
US7014993B1 (en) * 1997-08-21 2006-03-21 The Board Of Trustees Of The University Of Arkansas Extracellular serine protease
US5972616A (en) * 1998-02-20 1999-10-26 The Board Of Trustees Of The University Of Arkansas TADG-15: an extracellular serine protease overexpressed in breast and ovarian carcinomas
ES2263865T3 (es) * 1998-03-25 2006-12-16 Genentech, Inc. Homologo humano de neurotrimina.
AU1205901A (en) * 1999-10-14 2001-04-23 Board Of Trustees Of The University Of Arkansas, The Tumor antigen derived gene-16 (tadg-16): a novel extracellular serine protease and uses thereof
EP1252300B1 (en) * 2000-02-03 2011-01-19 Dendreon Corporation Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
AU6802801A (en) * 2000-03-01 2001-09-24 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same

Also Published As

Publication number Publication date
CA2362830A1 (en) 2000-09-08
EP1157035A1 (en) 2001-11-28
AU765471B2 (en) 2003-09-18
CA2362830C (en) 2012-08-21
EP1157035A4 (en) 2005-06-08
US6294663B1 (en) 2001-09-25
WO2000052044A1 (en) 2000-09-08
AU3720900A (en) 2000-09-21
US6291663B1 (en) 2001-09-18
JP2002537791A (ja) 2002-11-12

Similar Documents

Publication Publication Date Title
JP4558948B2 (ja) 卵巣癌において過剰発現される膜貫通型セリンプロテアーゼおよびその使用
US7067630B2 (en) Transmembrane serine protease overexpressed in ovarian carcinoma and uses thereof
US7939321B2 (en) TADG-15: an extracellular serine protease overexpressed in carcinomas
EP1056466B1 (en) Tadg-15: an extracellular serine protease overexpressed in breast and ovarian carcinomas
JP2003523524A5 (https=)
EP1887082A2 (en) TADG-15: An extracellular serine protease overexpressed in carcinomas
JP4253120B2 (ja) 新規な細胞外セリンプロテアーゼ
US7759103B2 (en) Extracellular serine protease
US7157084B2 (en) Extracellular serine protease
US7265216B2 (en) Transmembrane serine protease overexpressed in ovarian carcinoma and uses thereof
US7083790B2 (en) Extracellular serine protease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070227

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091208

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20100201

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20100205

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100308

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100315

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100406

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100712

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100722

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130730

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees